Document:

Exhibit 10.25

 

ASSIGNMENT, ASSUMPTION & SECOND
AMENDMENT

TO

PRODUCT MANUFACTURING & SUPPLY AGREEMENT

 

This Assignment, Assumption,
and Second Amendment (“Amendment”) is effective as of February __, 2012 (“Effective Date”) by and between
sanofi-aventis Canada Inc., with offices at 2150 St-Elzear Boulevard West, Laval, Quebec, Canada H7L4A8 (“Sanofi Canada”),
sanofi-aventis U.S. LLC, with offices at 55 Corporate Drive, Bridgewater, NJ 08807 (“Sanofi US”), and Cancer Prevention
Pharmaceuticals, LLC (CPP), having its principal place of business 1760 East River Road, Suite 250, Tucson, AZ 85718 (hereinafter
“CPP” and together with Sanofi Canada and Sanofi US, the “Parties”).

 

WHEREAS,
Sanofi Canada and CPP entered into a Product Manufacturing & Supply Agreement effective June 30, 2009 (as amended by a First
Amendment effective September 3, 2009, the “Agreement”); and

 

WHEREAS,
as of the date hereof the Parties wish to have Sanofi Canada assign and Sanofi US assume Sanofi Canada’s rights and obligations
under the Agreement; and

 

WHEREAS,
as of the date hereof the Parties wish to amend the terms of the Agreement as set forth below.

 

NOW, THEREFORE,
in consideration of mutual covenants the Parties agree as follows:

 

		1.	Assignment and Assumption. The Parties hereby acknowledge and agree that Sanofi Canada assigns,
and Sanofi US assumes, all of Sanofi Canada’s rights and obligations under the Agreement. References to “sanofi-aventis”
shall be understood to mean Sanofi US, or any Sanofi US affiliate where applicable and specified by Sanofi US or Sanofi Canada
in accordance with the terms of the Agreement.

 

		2.	A third “WHEREAS” paragraph is hereby added after the second “WHEREAS”
paragraph on page one of the Agreement as follows:

 

“AND WHEREAS the Parties
also wish to provide a mechanism by which CPP intends to engage sanofi-aventis under the terms of this Agreement for the manufacture
and supply of clinical and commercial quantities of any combination products containing DFMO (“DFMO Products”), including
but not restricted to an initial coformulated combination product containing DFMO and Sulindac (“CPP-1X/sul”) that
are developed by the Parties pursuant to a separate exclusive development agreement;”

 

		3.	Article 1. Interpretation. Article 1, Sections 1.1 u) and ff) are hereby replaced in their entirety
with the below:

 

“”Exclusivity Period”
means the period commencing on the Effective Date and continuing until the earlier of i) the expiration of this Agreement; ii)
the termination of this Agreement; and iii) the termination of the exclusivity rights granted herein; provided that solely with
respect to API, the exclusivity period shall terminate upon the earlier to occur of the first anniversary of CPP’s first
NDA submission for a Product in the Field and January 1, 2017. For clarification, exclusivity for Product (other than API) supply
from Sanofi to CPP in the Field will remain unaffected by the termination of exclusivity for API supply.

 

     

     

    

 

“Minimum Clinical Commitment”
means CPP’s obligation during the Clinical Period to purchase at least three (3) Batches of Clinical Product. To satisfy
the Minimum Clinical Commitment, CPP must purchase the first Batch within six (6) months of the Effective Date, the second Batch
within eighteen (18) months of the Effective Date and the third Batch on or before December 15, 2012. Notwithstanding the foregoing,
CPP’s Minimum Clinical Commitment shall be deemed satisfied in full upon CPP’s placement of an order for regulatory
filing registration batches in the United States, regardless of the number of Batches of Clinical Product purchased by CPP prior
to such order.”

 

		4.	Article 2. Exclusive Appointment. A new Section 2.7 is hereby added to the Agreement:

 

“2.7     Other DFMO Products.

 

a)        CPP appoints sanofi-aventis
as its exclusive developer of CPP-1X/sul. During the Exclusivity Period, CPP shall develop CPP-1X/sul for use in the Field solely
with sanofi-aventis.

 

b)       Subject to meeting conditions
set forth below, CPP shall appoint sanofi-aventis as its exclusive developer of DFMO Products other than CPP-1X/sul (“Other
DFMO Products”), pursuant to a separate development agreement, that includes exclusivity similar to those contained in Section
2.1 of this Agreement shall apply to such Other DFMO Products. In the event CPP decides to work with a third party to develop one
or more coformulated Other DFMO Products, prior to entering into a definitive agreement with a third party for development of such
Other DFMO Product(s), CPP shall provide sanofi-aventis with written notice of CPP’s intent to develop such Other DMFO Products
with a third party (“CPP Development Notice”), which notice shall include a reasonable description of the Other DFMO
Product to allow sanofi-aventis to evaluate the opportunity. Within seven (7) business days of the CPP Development Notice, sanofi-aventis
shall either (i) indicate in writing that sanofi-aventis’ intends to provide a quote for such development services (“Development
Response”), or (ii) indicate that sanofi-aventis does not desire to perform the development services. Should sanofi-aventis
fail to respond within the seven (7) business day period set forth above, sanofi-aventis shall be deemed to have elected not to
provide a quote for development services, and CPP shall have no further obligations to sanofi-aventis with respect to the development
of such Other DFMO Product(s). Should sanofi-aventis provide a Development Response, sanofi-aventis shall have an additional forty-five
(45) days from the date of the Development Response to provide CPP with a mutually agreeable written service order for such development
services. CPP agrees that if CPP determines in good faith that sanofi-aventis’s service order is the same or better than
the best third party quote received by CPP for such development services, CPP will agree to and execute such service order. If
the parties fail to agree on the specific service order during such period, CPP shall have no further obligations to sanofi-aventis
with respect to such development services. In no event shall this Section 2.7(b) be construed as preventing CPP from (i) obtaining
third party quotes with respect to any development services with respect to Other DFMO Products or (ii) developing Other DMFO Products
on its own.

 

     

     

    

 

c)      For clarification, nothing
in this Section 2.7 or this Agreement is intended to nullify sanofi-aventis’ appointment as exclusive commercial supplier
of all Products in the Field under Section 2.1.

 

d)      Except as otherwise specified
herein, it is understood that any Affiliate of sanofi-aventis may perform sanofi-aventis’ obligations set forth in this Agreement.
For the avoidance of doubt, sanofi-aventis shall remain jointly and severally liable with any such Affiliate for the performance
of its obligations under this Agreement.

 

e)     It is understood and agreed
to by the Parties that Affiliates of sanofi-aventis, may perform and manage services under this Agreement, and that sanofi-aventis
US LLC or other Affiliates may directly invoice CPP and receive payment from CPP under the terms of the Agreement.”

 

		5.	Article 4. Changes to Services. Article 4, is hereby modified by the addition of the below text
after Section 4.1:

 

“a)    Change Notices. Each
Party shall promptly notify the other Party in writing of any changes concerning pending processes, methods, specifications or
any quality related changes of which it becomes aware during the Services and which could affect the performance of the Services
or deliverables set forth in a Services Order or Purchase Order (each, a “Change Notice”). If a Change Notice recites
revisions that either Party in good faith believes will materially increase the scope of the Services, the effort required to deliver
deliverables, or the timeline to deliver deliverables under the applicable Services Order or Purchase Order, then within ten (10)
business days or any other time as agreed by both Parties separately after a Party’s receipt of such a Change Notice, sanofi-aventis
will deliver to CPP a written, revised Services Order or Purchase Order, as applicable, reflecting reasonable determination of
the revised Services, deliverables, delivery schedule, and payments and payment schedule, if any, that will apply to the implementation
of the revisions. If the Parties both agree to the revised Services Order or Purchase Order, then the Parties will execute it,
and upon execution, the revised Services Order or Purchase Order, as applicable, will supersede the then-existing Services Order
or Purchase Order, as applicable. Neither Party will unreasonably withhold or delay its agreement to a revised Services Order or
Purchase Order, except if the recipient of the Change Notice disputes in good faith the need for those changes, the Parties will
attempt to promptly and amicably resolve the dispute by discussions between the executive management of each Party. If the Parties
do not agree to the revised Services Order or Purchase Order within ten (10) business days after the receipt of the Change Notice
and neither Party elects to seek to resolve the dispute, the then-existing Services Order or Purchase Order will remain in full
force and effect, and neither Party will have any further obligation with respect to the applicable Change Notice.”

 

     

     

    

 

		6.	Article 6. Terms and Conditions of Sale. Article 6 is hereby amended by the addition of Section
6.24 as provided below:

 

“6.24 Service Orders. “Service
Order” means an order for services developed and executed by authorized representatives of each Party and referenced in a
Purchase Order, that specifies details of certain services to be performed by sanofi-aventis under this Agreement, including the
scope of work, compensation, timelines, deliverables (including documentation, as applicable), specifications, acceptance criteria,
and any other applicable terms for those services. The Parties agree that services performed under such Service Orders are subject
to the applicable terms of the Agreement, based on the particular scope of such Service Orders, and that in the event of any conflict
in terms between the Service Order(s) and this Agreement, the terms of this Agreement shall control, unless otherwise expressly
stated in such Service Order. Unless otherwise specified in a Service Order, CPP shall issue a Purchase Order to sanofi-aventis
to initiate the Services set forth in such Service Order.”

 

		7.	Article 10. Term and Termination. Article 10 is hereby amended by the addition of Section 10.3
f) and g) as provided below:

 

“f)   by sanofi-aventis (but
not by CPP), if CPP and sanofi-aventis fail to negotiate and execute an agreement for exclusive development activities for CPP-1X/sul
on or before the date which is one hundred and eighty (180) days (“Development Agreement Negotiation Period”) after
the full execution of that certain Assignment, Assumption & Second Amendment to Product Manufacturing & Supply Agreement
between the Parties. The Parties can extend the negotiation timeframe as the Parties may agree in writing. The right to terminate
under this subsection 10.3 f) shall expire one hundred and eighty (180) days after the expiration of the Development Agreement
Negotiation Period. For clarification, unless the Agreement is terminated, sanofi-aventis’s appointment as exclusive manufacturer
and supplier as set forth herein remains in full force and effect; and

 

g)   if CPP delivers a Change Notice
that is reasonably required for CPP to develop and commercialize a Product or DFMO Product in the Field and the Parties are unable
to agree upon such Change Notice through the dispute resolution procedure set forth in Section 4.1a).”

 

		8.	Except as expressly provided in this Amendment, all other terms and conditions of the Agreement
remain in full force and effect.

 

     

     

    

 

IN WITNESS WHEREOF, the Parties
have caused this Amendment to the Agreement to be executed by their duly authorized representatives as of the date first above
written.

 

	sanofi-aventis US LLC	 	CANCER PREVENTION PHARMACEUTICALS, LLC
	 	 	 	 	 
	By	/s/ Paul Chew	 	By	/s/ Jeffrey Jacob
	 	 	 	 	 
	Name 	Paul Chew	 	Name 	Jeffrey Jacob
	 	 	 	 	 
	Title	US CSO/CMO	 	Title	CEO
	 	 	 	 	 
	Date	3/5/12	 	Date	2/29/12
	 	 	 	 
	sanofi-aventis Canada Inc.	 	 	 
	 	 	 	 	 
	By	/s/ Hugh O’Neill	 	 	 
	 	 	 	 	 
	Name 	Hugh O’Neill	 	 	 
	 	 	 	 	 
	Title	President and CEO	 	 	 
	 	 	 	 	 
	Date	2/29/12Exhibit 10.26

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

	MASTER
    DEVELOPMENT AGREEMENT

 

BETWEEN THE UNDERSIGNED:

 

sanofi-aventis U.S. LLC, with offices
at 55 Corporate Drive, Bridgewater, NJ 08807 (“SANOFI”), acting for itself and on behalf of its Affiliates (as this
term is hereinafter defined),

 

hereinafter collectively referred to as
“SANOFI”,

 

On the one part,

AND:

 

Cancer Prevention Pharmaceuticals,
Inc., incorporated in the state of Delaware, USA and having a principal place of business at 1760
E. River Road, Suite 250, Tucson, AZ 85718, hereinafter referred to as "CPP”,

 

On the other part,

 

SANOFI and CPP are hereinafter individually
or collectively referred to as “Party” or “Parties”,

 

WITNESSETH:

 

WHEREAS, SANOFI and CPP entered into a
Product Manufacturing & Supply Agreement effective June 30, 2009, as amended by a First Amendment effective September 3, 2009
and further amended by that certain Assignment, Assumption & Second Amendment made effective February 29, 2012, (collectively,
the “Supply Agreement”), whereby SANOFI is the exclusive supplier of clinical and commercial quantities of Products
(as defined in the Supply Agreement) in the Field (as defined in the Supply Agreement) and whereby future arrangements are contemplated
under which SANOFI will be the exclusive developer of DFMO (as defined in the Supply Agreement) in combination with other ingredients,
which combination products are referred to in the Supply Agreement as the “DFMO Products;”

 

WHEREAS, the parties wish to enter into
this Master Development Agreement under which SANOFI and/or certain of SANOFI's Affiliates shall provide certain services to CPP
in connection with the development of DFMO Products; and

 

    	 	1	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

WHEREAS, CPP desires that SANOFI provide
such services to CPP after the Effective Date, and SANOFI agrees to provide such services or to cause its Affiliates to provide
such services to CPP pursuant to the terms of this Agreement.

 

NOW, THEREFORE, IN CONSIDERATION OF
THE PREMISES AND THE MUTUAL COVENANTS AND AGREEMENTS HEREIN CONTAINED, THE PARTIES AGREE AS FOLLOWS:

 

ARTICLE
1 - DEFINITIONS

 

The following terms as used in this Agreement
shall have the meaning set forth in this Article 1:

 

		1.1	“Agreement”
                                         shall mean the present Master Development Agreement together with all its attached
                                         exhibits, as they may be amended or otherwise modified from time to time.

 

		1.2	“Affiliate”
                                         of a Party to this Agreement
                                         means any entity that controls, is controlled by, or is under common control with such
                                         Party. For the purposes of this definition, an entity shall be deemed to control another
                                         entity if it owns or controls directly or indirectly a majority of the voting equity
                                         or assets of the other entity (or other comparable ownership interest for an entity other
                                         than a corporation).

 

		1.3	"Background
                                         IP" shall mean a Party's Intellectual Property used in connection with the performance
                                         of the Services including any patented technology, know-how, trade secret, invention
                                         and proprietary information (including Confidential Information) that: (a) was in the
                                         Party's possession prior to the date of the disclosure of the Confidential Information;
                                         (b) represents a reduction to practice of that Party’s conception that was made
                                         before the Effective Date; (c) any Intellectual Property subsequently generated or acquired
                                         independently by a Party outside the scope of this Agreement without reference to the
                                         other Party’s Confidential Information; and (d) any Intellectual Property Rights
                                         associated with any of the foregoing.

 

		1.4	“Confidentiality
                                         Agreement” means that certain confidentiality agreement between SANOFI and
                                         CPP made effective January 28, 2009 (attached hereto as Exhibit 2).

 

		1.5	"Confidential
                                         Information" has the meaning given that term in the Confidentiality Agreement.

 

		1.6	“Exclusivity
                                         Period” has the same meaning given that term in the Supply Agreement.

 

    	 	2	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		1.7	“Improvement”
                                         means any and all information, know-how, results, designs, inventions, developments,
                                         improvements, modifications, innovations, synthesis and associated Intellectual Property
                                         Rights, whether patentable or not, developed, generated or obtained by SANOFI in the
                                         course of performing, or within the scope of, the Services and/or as a result of the
                                         Services, related to the process or methods of manufacturing DFMO Products. For the avoidance
                                         of doubt, an “Improvement” does not include any information, know-how, results,
                                         designs, inventions, developments, improvements, modifications, innovations, synthesis
                                         and other associated Intellectual Property Rights, whether patentable or not, developed,
                                         generated or obtained by SANOFI in the course of performing, or within the scope of,
                                         the Services and/or as a result of the Services, pertaining to the uses or formulation
                                         of DFMO Products; rather, those items and matters will constitute Results.

 

		1.8	“Intellectual
                                         Property” has the meaning given that term in the Supply Agreement.

 

		1.9	“Intellectual
                                         Property Rights” means any and all legal rights granted with respect to Intellectual
                                         Property under or through copyrights, trademarks, patents, patent applications, or other
                                         governmental registrations or that are afforded Intellectual Property under law, including
                                         without limitation the right to file or claim priority rights or rights under any treaty
                                         with regard to the same.

 

		1.10	“Regulatory
                                         Authority(ies)” means any governmental agency having jurisdiction over the
                                         activities contemplated under this Agreement, including but not limited to the authorization
                                         to manufacture or market DFMO Product in any territory.

 

		1.11	“Requirements”
                                         shall mean the tests, procedures and other activities detailed in a “Development
                                         Requirements” exhibit attached to a particular SOW that are required to assess
                                         the suitability of the manufacturing processes for DFMO Products in accordance with the
                                         Specifications. For the avoidance of doubt, the Requirements are deemed to be CPP Confidential
                                         Information.

 

		1.12	“Results”
                                         shall mean all results, information, data (including raw data), documents, know-how,
                                         products, processes, analytical developments, methods, formulations, software, devices,
                                         discoveries, materials, reports, samples, inventions, and whether patentable or not,
                                         generated or obtained in whatever form in the course of performing, or within the scope
                                         of, the Services and/or as a result of the Services, related to any of the DFMO Product,
                                         its formulation, its uses except to the extent any of the foregoing constitute an Improvement.
                                         For the avoidance of doubt, all Results are deemed to be CPP’s Confidential Information.

 

		1.13	“Services”
                                         shall mean activities and tasks of SANOFI detailed in a particular SOW.

 

		1.14	“Statement
                                         of Work” or “SOW” shall mean any statement of work, executed
                                         by the parties, describing particular services to be provided by SANOFI to CPP, subject
                                         to the terms of this Agreement, including Section 4.1 below. Upon execution and delivery
                                         by both parties, a SOW shall become part of this Agreement. In the case of any conflict
                                         between the terms of this Agreement and any SOW, the terms of this Agreement will control.
                                         A form of SOW is attached hereto as Exhibit 1.

 

    	 	3	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		1.15	"Specifications"
                                         shall mean the specifications of the DFMO Product set forth in a particular SOW.
                                         For the avoidance of doubt, the Specifications are deemed to be CPP Confidential Information.

 

		1.16	“Term”
                                         shall mean the initial Term of this Agreement as defined in Article 8 hereof,
                                         and any renewal period thereafter, if any.

 

ARTICLE
2 - SCOPE OF THE AGREEMENT; EXCLUSIVITY

 

This Agreement sets forth the terms and
conditions under which CPP entrusts SANOFI for the performance of the Services and SANOFI hereby agrees to perform such Services,
in accordance with the terms and conditions set forth in this Agreement and the applicable SOWs.

 

SANOFI shall use its commercially reasonable
efforts to achieve the estimated timelines with respect to the Services and complete the Requirements, it being understood by
the Parties that SANOFI shall provide CPP with the agreed deliverables, and in accordance with the Specifications, in due time
but otherwise shall not guarantee a successful result with respect to the DFMO Product, in terms of its therapeutic qualities
and achievements.

 

Subject to the conditions of exclusivity
and termination of exclusivity set forth below, and during the Exclusivity Period: (a) the Services pertaining to DFMO Products
provided hereunder are to be provided exclusively to, and for the benefit of, CPP; (b) SANOFI may not enter into any agreement
to develop DFMO Products for any third parties; and (c) CPP may not contract with a third party to perform services related to
DFMO Products, except as provided below. Except as provided in the immediately preceding sentence, nothing contained in this Agreement
may be construed to obligate CPP to: (i) refrain at any time from disclosing any of its Confidential Information to any person;
(ii) proceed with any transaction with any person apart from transactions from the development of DFMO Products not permitted
by this Agreement during the Exclusivity Period; or (iii) create any joint venture, partnership, agency or further relationship
between the parties In addition to the circumstances addressed in the immediately following paragraph, if SANOFI is unable to
perform the Services with regard to one or more DFMO Products in accordance with the SOW and within its scope, to provide the
deliverables specified in the SOW that satisfy the applicable specifications, or to obtain Results with regard to one or more
DFMO Products that satisfy the applicable requirements set forth in an applicable SOW, or otherwise declines to perform DFMO Development
Services for CPP, then CPP may, on ten days’ advance written notice to SANOFI, terminate SANOFI’s exclusivity as a
developer hereunder with regard to those DFMO Products and Services. Additionally, the exclusivity conferred to SANOFI under this
Agreement will expire or terminate with the termination of exclusivity under Article 2 of the Supply Agreement or the expiration
or termination of the Exclusivity Period under the Supply Agreement.

 

    	 	4	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

If CPP seeks to work with a third party
to develop one or more DFMO Products other than CPP-1X/sul, then before entering into a definitive agreement with a third party
to develop those DFMO Product(s), CPP shall provide SANOFI with written notice of CPP’s intent to develop those DMFO Products
with a third party ("CPP Development Notice"). The Development Notice shall include a reasonable description of the
DFMO Product to allow SANOFI to evaluate the opportunity. Within seven (7) business days after the CPP Development Notice, SANOFI
shall either: (A) indicate in writing that it intends to provide a quote for those development services ("Development Response"),
or (B) indicate that it does not desire to perform the development services. If SANOFI fails to timely respond, SANOFI shall be
deemed to have elected not to provide a quote for those development services, and CPP will be free to enter into a definitive
agreement with a third party for the development of those DFMO Product(s). If SANOFI provides a Development Response, SANOFI shall
have an additional forty-five (45) days from the date of the Development Response to provide CPP with a written service order
for those development services. If CPP determines, in good faith, that the terms of SANOFI’s service order are at least
as favorable or more favorable to CPP than the other third-party quotes received by CPP for those development services, CPP will
agree to and execute SANOFI’s service order. If the parties fail to agree on the terms of the service order for those development
services during that 45-day period, CPP will be free to enter into a definitive agreement with a third party for the development
of those DFMO Product(s). In no event may the foregoing be construed to prevent CPP from: (I) obtaining third party quotes with
respect to any development services for DFMO Products or (II) developing DMFO Products on its own.

 

The foregoing is not intended, and may
not be interpreted to nullify SANOFI’s appointment as exclusive commercial supplier in the Field under Section 2.1 of the
Supply Agreement.

 

ARTICLE
3 – JOINT SERVICES COMMITTEE

 

Each of the Parties
shall promptly after the execution of this Agreement appoint one or more appropriate persons with appropriate technical expertise
to serve as members of a Joint Services Committee to supervise the Services and resolve or attempt to resolve any technical difficulties
that may arise. Either Party may change its appointees at any time by a notice in writing to the other Party. The Joint Services
Committee shall meet when needed or when called for by other provisions of this Agreement but at least on a quarterly basis during
the Term. Meetings may be held in person, by telephone or by any other means and minutes shall be taken of any such meeting.

 

ARTICLE
4 – PERFORMANCE OF THE SERVICES

 

		4.1	Performance
                                         of the Services. 

 

Subject to the terms and conditions
of this Agreement and CPP’s request and direction, SANOFI will perform for CPP the Services described in SOWs executed by
the parties. Each SOW shall contain detailed Service descriptions, Specifications, and Requirements for the Services to be performed,
and may also include but not be limited to timelines, payment terms, and deliverables.

 

    	 	5	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		4.1.1	SANOFI warrants to the exclusion
                                         of any other warranties in this Agreement other than those set forth in Article 14 and
                                         without exclusion or limitation of any warranties provided under the Supply Agreement,
                                         that:

 

		(i)	the Services shall be performed
                                         in a competent and professional-like manner, in accordance with good, generally recognized
                                         professional standards applicable to those similarly situated in SANOFI’s industry,
                                         and by personnel suitably qualified to perform the Services;

 

		(ii)	SANOFI is the lawful owner,
                                         licensee or has proper legal rights to use the equipment, facilities, methods, technology
                                         and programs that SANOFI or its Affiliates will use for providing the Services and will
                                         meet the requirements of all applicable laws, regulations and standard inspection criteria;

 

		(iii)	Where applicable, all deliverables
                                         will satisfy the applicable specifications set forth in the pertinent SOW;

 

		(iv)	SANOFI has the right to assign
                                         the Results and corresponding Intellectual Property Rights to Client, and otherwise grant
                                         the rights granted to Client under this Agreement free and clear of any encumbrances;

 

		(v)	SANOFI has not entered into any
                                         agreement that would grant any third party, or otherwise create any encumbrance upon,
                                         any Results;

 

		(vi)	in providing the Services and
                                         producing the Results, Contractor will not knowingly infringe or misappropriate any Intellectual
                                         Property Rights of any third party; and

 

		(vii)	the representations and warranties
                                         of SANOFI set forth in Section 9.2 (except for 9.2(i)) of the Supply Agreement are incorporated
                                         herein by this reference as if set forth in full, mutatis mutandis.

 

		4.1.2	Each Party shall notify the
                                         other Party in writing, as soon as it becomes aware thereof, of any changes in the pending
                                         processes, methods, specifications and/or manufacturing processes, which could affect
                                         the performance of the Services and/or the Results pursuant to the Requirements. To that
                                         respect both Parties shall endeavor to agree upon any necessary actions and schedule
                                         modification resulting therefrom, including if needed appropriate adjustments to the
                                         prices defined in Section 5.1 in accordance with the procedures relating to Change Orders
                                         in Section 4.1.4 below. Such Change Order shall be approved, in writing, by the Parties
                                         before implementation.

 

		4.1.3	SANOFI shall generate and
                                         maintain adequate, true and accurate tangible or electronic books, records, test and
                                         laboratory data, reports and other information relating to the Services conducted under
                                         this Agreement and in particular of all Results, data and developments made pursuant
                                         to its efforts under this Agreement (collectively, the “Records”). Upon request
                                         by CPP, SANOFI shall provide any and all Records. In addition to any interim reports
                                         required under a particular SOW, upon completion of Services outlined in a particular
                                         SOW, SANOFI shall prepare a final report summarizing all Services and Results related
                                         to such particular SOW, containing all Results. SANOFI must retain the Records for at
                                         least five (5) years following the date of completion of the Services under the SOW to
                                         which the Records and, upon CPP’s request, will deliver them to CPP at CPP’s
                                         expense and direction.

 

    	 	6	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		4.1.4	If necessary for the performance
                                         of the Services, CPP shall have the right
                                         to give technical and scientific direction in relation to the development process and
                                         Services provided under any particular SOW. SANOFI shall promptly consider implementation
                                         of such direction. If SANOFI believes, in good faith, that the implementation of that
                                         direction will materially change a particular SOW by increasing the scope of the Services,
                                         the effort required to deliver deliverables, or extending the timeline to complete the
                                         Services, then within ten (10) business days after SANOFI’s receipt of CPP’s
                                         technical or scientific direction or any other time as the Parties may determine, SANOFI
                                         will so notify CPP in writing (each such writing, a "Change Notice") reflecting
                                         SANOFI’s reasonable determination of the consequent changes to the applicable portion
                                         of the SOW, including any applicable changes to the Services, deliverables, delivery
                                         schedule, and payments and payment schedule, if any, that will apply to the implementation
                                         of the direction. The Parties will diligently negotiate the proposed terms of the Change
                                         Notice in good faith, although neither party is obligated to agree to any Change Notice.
                                         Upon full execution of the agreed-upon Change Order, the Change Order will be effective
                                         and constitute an amendment to the applicable SOW. Neither Party will unreasonably withhold
                                         or delay its agreement to revisions to the SOW, except if either party disputes in good
                                         faith the need for those changes, the Parties will attempt to promptly and amicably resolve
                                         the dispute by discussions between the executive management of each Party. If the Parties
                                         do not agree on the revisions to the applicable SOW within ten (10) business days after
                                         CPP’s receipt of the Change Notice and neither Party elects to seek to resolve
                                         the dispute through discussion between executive management, the then-existing SOW will
                                         remain in full force and effect without regard to the Change Notice, and neither Party
                                         will have any further obligation with respect to the applicable Change Notice.

 

		4.1.5	If CPP elects to have an employee
                                         or agent visit SANOFI’s facilities related to the Services, CPP will inform SANOFI,
                                         in writing and with sufficient notice, of the name(s) of its employee(s) visiting the
                                         premises. In this case, such employee must comply with SANOFI’s policy with respect
                                         to visitors, control, security, hygiene, health and safety rules applicable at the SANOFI’s
                                         premises. SANOFI will communicate these instructions to CPP prior to the arrival of CPP’s
                                         personnel on SANOFI’s premises. Such CPP personnel shall be informed of such rules
                                         and CPP shall be responsible for the respect of said rules by its personnel. Each visit
                                         shall be scheduled by mutual agreement of the parties and shall not exceed more than
                                         two business days per visit. CPP will not have the right to conduct more than two visits
                                         per calendar year.

 

    	 	7	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		4.1.6	If the parties mutually agree
                                         that an agent or employee of SANOFI has to visit CPP’s facilities to perform services
                                         for the purpose of the Services on any CPP’s site, SANOFI and CPP will agree upon
                                         dates and SANOFI will inform CPP, in writing and with sufficient notice, of the name(s)
                                         of its employee(s) visiting the premises. In this case, such employee must comply with
                                         CPP’s policy with respect to visitors, control, security, hygiene, health and safety
                                         rules applicable at the CPP’s premises. CPP will communicate these instructions
                                         to SANOFI prior to the arrival of SANOFI’s personnel on CPP’s premises. Such
                                         SANOFI’s personnel shall be informed of such rules and SANOFI shall be responsible
                                         for the respect of said rules by its personnel.

 

ARTICLE
5 - PRICES - INVOICING - PAYMENTS

 

		5.1	Remuneration

 

In consideration for the performance of
the Services by SANOFI hereunder, CPP shall pay to SANOFI for the completion of the Services as set forth in a particular SOW.
Except as set forth in the SOW, the prices are exclusive of taxes, duties, such as sales, export, import, value added tax which
shall be added to the prices as appropriate.

 

		5.2	Payment

 

SANOFI shall invoice CPP as specified
in a particular SOW. CPP’s payment of undisputed amounts is due thirty (30) days, after the date of invoice. The parties
understand and agree that SANOFI may suspend performance of any Services for CPP should any undisputed amounts under an invoice
remain unpaid to SANOFI after the date ten (10) business days after SANOFI’s written notice to CPP of the failure to timely
pay that amount.

 

ARTICLE
6- MATERIALS AND DOCUMENTATION PROVIDED BY CPP, CERTAIN WARRANTIES

 

		6.1	Material(s)

 

In order to permit SANOFI to
perform the Services, each SOW will specify that information and other materials, whether documentary or chemical, (collectively,
the “Materials”) that SANOFI believes is necessary for performing the Services under the terms and conditions of this
Agreement. For the avoidance of doubt, all Materials are deemed to be CPP’s Confidential Information.

 

6.2    CPP
warrants that it will provide SANOFI with all information in its possession, at the time of execution of the Agreement, relating
to environmental, toxic or other hazardous properties relating to or in connection with the any materials actually first provided
to Sanofi by CPP. CPP’s obligation to provide information to SANOFI includes but is not limited to providing information
where there is potentially any toxicity concerns related to the CPP Materials. In such case, CPP shall supply SANOFI with what
shall be titled “Material Safety Data Sheets” corresponding to the CPP Materials.

 

    	 	8	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

Upon completion of Services
for a particular SOW, any unused quantity of Active Ingredient or other Materials utilized in the manufacture of DFMO Product(s),
if any, shall be, as CPP will decide: (i) returned by SANOFI to CPP; (ii) destroyed by SANOFI on the expense of CPP (in which
latter case SANOFI will provide CPP with a certificate evidencing the proper destruction) upon completion of the Services; or
(iii) retained by SANOFI for use in other SOWs.

 

		6.3	SANOFI Custody of Materials

 

While the Materials are in
SANOFI’s custody, SANOFI shall be liable for the proper storage, use and handling of the Materials. If any Materials are
improperly used by SANOFI outside the scope of Services, or destroyed or damaged by SANOFI, and such Materials cannot be utilized
for Services under this Agreement SANOFI will be responsible for the cost of replacing those Materials.

 

		6.4	Payment for Shipment

 

CPP is responsible for arranging
and paying for the shipment of the Materials and the CPP Materials. All Materials and CPP Materials will be shipped to SANOFI
FCA (Incoterms 2010) the plant at which the Services with respect to those Materials and CPP Materials will be performed.

 

		7	- INTELLECTUAL PROPERTY

 

		7.3	CPP Confidential Information.

 

SANOFI expressly agrees that
all CPP's Confidential Information is and shall remain the sole property of CPP, and nothing herein contained shall be
deemed to transfer to SANOFI any right, including property rights, under any CPP's Confidential Information, nor to grant SANOFI
any rights to or license under any of CPP’s Intellectual Property Rights or any related or subsequent know-how or developments
during the term of this Agreement or at any time thereafter, except for the grant of rights specifically set forth herein.

 

		7.4	SANOFI Confidential Information.

 

CPP expressly agrees that all
SANOFI's Confidential Information is and shall remain the sole property of SANOFI, and nothing herein contained shall be deemed
to transfer to CPP any right, including property rights, under any SANOFI’s Confidential Information, nor to grant CPP any
rights to or license under any of SANOFI’s patents, patent applications, know-how, patterns or trademarks relating to SANOFI's
Information, equipment or know-how or any related or subsequent developments or improvement, during the term of this Agreement
or at any time thereafter, except for the grant of rights specifically set forth herein.

 

    	 	9	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		7.5	Background IP 

 

		(a)	Each
                                         Party shall retain all of its right, title and interest in and to its own Background
                                         IP. Each Party acknowledges that ownership of and
                                         title to the other Party’s Background IP, including the goodwill associated with
                                         its trade-marks, shall at all times remain with the other Party, and each Party shall
                                         not dispute or contest or assist others to dispute or contest the validity of any of
                                         the other Party’s Background IP. In addition, if a Party so disputes or contests
                                         or assists others to dispute or contest the validity of any of the foregoing rights of
                                         the other Party, the other Party shall have the right to terminate this Agreement immediately
                                         upon written notice.

 

		(b)	During the term of this Agreement,
                                         CPP hereby grants to SANOFI a limited license under its rights to its Background IP,
                                         solely to the extent necessary for SANOFI to perform the Services and without payment
                                         of any additional fees.

 

		7.6	Assignment of Results and Intellectual
                                         Property; Ownership of Improvements.

 

All Results and the Intellectual
Property and the Intellectual Property Rights associated with or pertaining to the Results shall become automatically and immediately,
at all times, both during and after the expiry or termination date of this Agreement, the exclusive property of CPP, which
has the right, at its sole cost and in its sole discretion, to apply for and obtain Intellectual Property Rights in the
United States and all foreign countries under any relevant and applicable intellectual property laws without any limitation whatsoever
(domain, duration, territory, etc), and without any additional payment to SANOFI. To that end, SANOFI hereby assigns to CPP all
its rights, title and interest in and to the Results and the Intellectual Property and Intellectual Property Rights associated
with them. The rights, title and interests so assigned shall include, but not be limited to, rights of reproduction, adaptation,
translation, exploitation and display, worldwide, in any form, on any medium and for the legal duration of protection of Intellectual
Property Rights in the country of exploitation. Any and all Improvements and the Intellectual Property Rights associated with
or pertaining to any and all Improvements will be the property of SANOFI, and will be included in and be the subject of the licenses
granted by SANOFI to CPP under Article 11 of the Supply Agreement. If SANOFI elects not to pursue patent protection for any Improvement,
it must promptly provide CPP written notice of that election and offer to assign that Improvement to CPP. On or before the date
sixty days after CPP’s receipt of SANOFI’s written notice, CPP must provide SANOFI written notice of whether CPP elects
to accept assignment of that Improvement. If CPP timely notifies SANOFI of its election to accept assignment of that Improvement,
then that Improvement will be deemed part of, and incorporated into, the Results and SANOFI’s obligations with respect to
the Results will be applicable to that Improvement. If CPP does not timely notify SANOFI of its election, then CPP will be deemed
to have declined to accept assignment of that Improvement.

 

    	 	10	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		7.7	Application of SANOFI Obligations
                                         to Employees and Agents.

 

SANOFI further covenants that:
(a) its employees, agents, contractors or any persons working with SANOFI in such ways that they can be considered as inventors
to any patentable invention or authors of any copyrightable material that, in either event, is generated as Results, are subject
to obligations to SANOFI so as to enable SANOFI to comply with its obligations under this Agreement; (b)
it will not encumber with, or place or allowed to be placed on, any Results or any Intellectual Property or Intellectual
Property Rights associated with them any restrictions, mortgages, liens, pledges, or security interests; or (c)
it will not grant any rights or interest in the Results or any Intellectual Property or Intellectual Property Rights associated
with them to any third party.

 

		7.8	Continuing Rights of CPP.

 

All quantities of DFMO Products
or Materials, as well as all information, data and documents supplied to SANOFI by CPP or obtained by SANOFI within the performance
of the Services are and shall remain the exclusive property of CPP.

 

		7.9	Reasonable Assistance and Further
                                         Assurances.

 

Any Intellectual Property Rights
that may be based on, or applied for on the basis of, the Results shall be the exclusive property of CPP or its designee (hereinafter
the "Applicant"). They shall be filed in the name and at the cost of the Applicant. If reasonably requested by the Applicant,
SANOFI shall, and shall cause its employees and consultants that may have contributed to the creation, making, inventing, development
or production of any Results or Intellectual Property associated therewith, to promptly execute and delivery any and all documents
that the Applicant may deem necessary or desirable to prepare, file for, obtain and maintain, any Intellectual Property Rights
in any country of the world, and to promptly provide the Applicant with all other necessary assistance, even after termination
of the Agreement, in order to enable it to apply for, obtain, maintain in force and defend such patents, without any payment other
than the reimbursement of the expenses incurred by SANOFI for the time devoted to such assistance, subject to prior written approval
of CPP on such expenses.

 

		7.10 	Rights in Bankruptcy.

 

The Parties acknowledge and
agree that all rights and licenses granted under or pursuant to this Agreement to CPP are, and shall otherwise be deemed to be,
for purposes of Section 365(n) of the United States Bankruptcy Code and other similar foreign laws, licenses of rights to
“intellectual property” as defined under Section 101 of the United States Bankruptcy Code or other similar foreign
laws. CPP, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections
under the U.S. Bankruptcy Code or other similar foreign laws.

 

		7.11 	Continued Effectiveness.

 

The provisions of this Article
shall remain in full force and effect after the expiration or termination of this Agreement.

 

    	 	11	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

  

		8	- TERM AND TERMINATION

 

		8.1	Term.

 

This Agreement shall be effective
as from the date this Agreement is fully executed (the “Effective Date”), and shall, unless terminated earlier under
the provisions of this Agreement, expire upon the expiration of the Exclusivity Period. This Agreement shall be extended or renewed
only by means of a written amendment signed by and between the Parties and shall not be tacitly extended or renewed.

 

		8.2	Termination of Agreement.
                                         This Agreement may be terminated in the following cases:

 

		(i)	If the other Party breaches any
                                         of the material terms of this Agreement and fails to remedy such breach within thirty
                                         (30) days after notice requiring it to do so, the non-breaching Party shall have the
                                         right to terminate this Agreement upon one month prior written notice. Termination of
                                         this Agreement pursuant to this Subsection shall cause all SOWs then outstanding to concurrently
                                         terminate with the termination of this Agreement, unless the Parties otherwise agree
                                         in writing If SANOFI is the breaching party, CPP will have
                                         no obligation to make further payments after termination except for Services already
                                         performed by SANOFI up to the date of termination that resulted in any deliverable specified
                                         in the SOW being provided to and accepted by CPP or that achieved the Results applicable
                                         to those Services specified in the SOW, where Results are specifically outlined in such
                                         SOW, and where such Results are specifically stated to be an obligation of SANOFI within
                                         such SOW;

 

		(ii)	by a Party if the other Party
                                         hereto files an order (or has filed against or on its behalf such order) of bankruptcy
                                         under any applicable law, or becomes insolvent or bankrupt, makes an assignment for creditors,
                                         whether voluntary or involuntary, is unable to pay its debts as they become due, or enters
                                         into liquidation, if applicable;

 

		(iii)	By CPP, upon ninety (90) days
                                         prior written notice to SANOFI, if CPP decides development is substantially delayed or
                                         terminated or if CPP determines in good faith that the commercial potential for DFMO
                                         containing products, does not warrant furtherance of the project;

 

		(iv)	By SANOFI, upon nine (9) months
                                         prior written notice to CPP, for any reason, in which event no additional SOWs shall
                                         be executed after the date of receipt of termination notice, but SANOFI must complete
                                         all Services to be performed under any SOWs outstanding as of the date of SANOFI’s
                                         termination notice;

 

		(v)	By CPP if a Force Majeure event
                                         as defined herein lasts for more than one (1) month pursuant to Article 12 of
                                         the Agreement; or

 

		(vi)	Upon termination or expiration
                                         of the Supply Agreement.

 

    	 	12	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		8.3	Termination of SOWs.

 

CPP may, in its sole discretion,
terminate any SOW upon sixty (60) days prior written notice to SANOFI. If CPP so terminates a SOW, unless the Parties otherwise
agree in writing, each other SOW then in progress will not be affected and the Services with respect to which will continue to
be conducted, billed, and paid for until completion of each such SOW, which will continue to be governed by this Agreement as
if not terminated. In the event of termination of any SOW, CPP is obligated to pay SANOFI only those fees earned by SANOFI for
Services performed through the effective date of termination and any reimbursable expenses incurred in the performance of the
Services under the terminated SOW.

 

		8.4	Surviving Obligations.

 

Except to the extent otherwise
expressly provided in this Agreement, each Party’s rights and obligations under each provision of this Agreement that accrued
before the effective date of expiration or earlier termination or that, by their nature, should survive the termination of this
Agreement, survive any termination of this Agreement and continue in full force and effect. In addition to any provision of this
Agreement that expressly provides for acts or obligations to continue beyond the termination or expiration of this Agreement,
this Section and Section 4.1.1, 4.1.3 (with respect to the obligation and time period for retention of Records and CPP’s
right to inspect and take possession of the Records), and 8.5, and Articles 7, 10, 11, 12, 14 and 15, and corresponding definitions
or provisions that may be suitable for giving those provisions their intended meaning or affect, survive the expiration or earlier
termination of this Agreement

 

		8.5	Rights and Obligations upon
                                         Expiration or Termination.

 

SANOFI may, at its sole discretion,
terminate any SOW upon providing CPP with nine (9) months prior written notice.

 

Termination of a SOW, or termination
or expiration of the Agreement will not relieve a party from any liability that, at the time of such termination or expiration,
has already accrued to the other party, or which is attributable to the period prior to such expiration or termination, except
as may otherwise be set forth herein. The termination of this Agreement or a SOW shall be without prejudice to any right or obligations
of either Party under any Articles of this Agreement that, by nature, shall survive termination. Promptly after the termination
of this Agreement, SANOFI must destroy or return to CPP all copies of Materials and documents or copies thereof in tangible form,
including electronic or magnetic form, containing any CPP Confidential Information. As soon as practicable after termination of
this Agreement, SANOFI must deliver to CPP any and all Results and Records, reasonably organized, catalogued and indexed.

 

    	 	13	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		9	– AUTHORIZATIONS
                                         - REGULATORY OBLIGATIONS

 

Each Party shall maintain all licenses,
permits and registrations in connection with its obligations under this Agreement. With respect to the DFMO Product(s), SANOFI
shall provide commercially reasonable support to CPP when CPP submits any documents for filing purpose to the Regulatory Authorities
during the term of this Agreement, which may include filings or engaging in any communications with, or respond to any questions
or requests from, any Regulatory Authorities in the manner required under Article 8 of the Supply Agreement.

 

		10	– INDEMNIFICATION

 

		10.1	Indemnification for Direct
                                         Claims.

 

		10.1.1	In the event of any claim by
                                         CPP under the warranty set forth in clauses (i) (ii) or (iii) of Subsection 4.1.1 above,
                                         SANOFI shall only be responsible for promptly correcting such deficient Services and,
                                         to the extent applicable, promptly replacing the DFMO Products, at SANOFI’s sole
                                         expense.

 

		10.1.2	Except as otherwise provided
                                         in Section 10.2, each Party shall indemnify the other Party, its Affiliates and its respective
                                         officers, directors, managers, agents, representatives and employees (the “Indemnifiable
                                         Parties”) against, and hold them harmless from any and all direct claims, losses
                                         or damages, excluding lost profits, revenues or opportunities of any kind but including
                                         reasonable attorney’s fees, suffered by any Indemnifiable Party as a result of
                                         the gross negligence or willful misconduct of the other Party under this Agreement.

 

		10.1.3	Except as otherwise provided
                                         in Section 10.1.1 and 10.1.2, each Party shall indemnify the other Party’s Indemnifiable
                                         Parties against, and hold them harmless from any and all direct claims, losses or damages,
                                         excluding lost profits, revenues or opportunities of any kind but including reasonable
                                         attorney’s fees, suffered by any Indemnifiable Party as a result of the breach
                                         of this Agreement by the other Party under this Agreement.

 

		10.1.4	In the event of a claim (other
                                         than a Third Party Claim as defined in Section 10.3) made by one Party and/or its Affiliates
                                         under Section 10.1 as the case may be (a “Direct Claim”), the Indemnifiable
                                         Party shall notify such Direct Claim in writing to the indemnifying party (“Indemnifying
                                         Party”) with reasonable promptness, specifying the nature and grounds of such
                                         Direct Claim and the amount or estimated amount thereof (which estimate is for information
                                         only and shall not be conclusive of the final amount of such Direct Claim nor actionable);
                                         provided, however, that the prompt giving of such notice shall not be condition precedent
                                         to indemnification under this Agreement except to the extent that the Indemnifying Party
                                         is materially prejudiced by any delay in receiving such notice. The Indemnifiable Party
                                         shall further provide to the Indemnifying Party as soon as it becomes available any information
                                         in relation to the Direct Claim.

 

    	 	14	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		10.2	Indemnification for Third Party
                                         Claims.

 

In the event of a claim by a third party
arising in connection with the provision of any of the Services (“Third Party Claim”), the following rules
shall apply:

 

		10.2.1	SANOFI shall indemnify CPP and
                                         its respective officers, directors, managers, agents, representatives and employees (the
                                         “CPP’s Indemnified Parties”) against, and hold CPP’s Indemnified
                                         Parties harmless from any and all direct claims, losses or damages, including without
                                         limitation reasonable attorney’s fees, arising out of, or resulting from, any Third
                                         Party Claim asserted against any CPP’s Indemnified Party for any losses or damages
                                         as a result of (i) any breach by SANOFI of its representation and warranty as set forth
                                         in Section 4.1 or in Section 14.6 hereto, (ii) the negligence or willful misconduct of
                                         SANOFI and/or its Affiliates under this Agreement, (iii) SANOFI’s violation of
                                         any applicable law or regulations, or (iv) SANOFI’s breach of its obligations under
                                         this Agreement, except to the extent such claims, losses or damages are caused by any
                                         event, action or omission that CPP is obligated to indemnify SANOFI under Subsection
                                         10.2.2..

 

		10.2.2	CPP shall indemnify SANOFI,
                                         its Affiliates and its respective officers, directors, managers, agents, representatives
                                         and employees (the “SANOFI’s Indemnified Parties”) against,
                                         and hold SANOFI’s Indemnified Parties harmless from any and all direct claims,
                                         losses or damages, including without limitation reasonable attorney’s fees, arising
                                         out of, or resulting from, any Third Party Claim asserted against any SANOFI’s
                                         Indemnified Party for any losses or damages as a result of (i) the negligence or willful
                                         misconduct of CPP and/or its Affiliates under this Agreement, (ii) CPP’s violation
                                         of any applicable law or regulations, or (iii) CPP’s breach of its obligations
                                         under this Agreement; except to the extent such claims, losses or damages are caused
                                         by any event, action or omission that SANOFI is obligated to indemnify CPP under Subsection
                                         10.1.2.

 

		10.2.3	In the event of a Third Party
                                         Claim, the Indemnifiable Party shall with reasonable promptness send to the indemnifying
                                         party (“Indemnifying Party”) a written notice specifying the nature
                                         of such claim or demand and the amount or estimated amount (which estimate shall not
                                         be conclusive of the final amount of such claim and demand) (a “Third Party
                                         Claim Notice”). The Indemnifying Party shall take such action to avoid, defend,
                                         dispute, resist, appeal or compromise such claim as it may determine, after consulting
                                         the Indemnifiable Party and taking into account its reasonable comments and requests.
                                         The Indemnifiable Party shall take, at the Indemnifying Party’s expense, all reasonable
                                         steps to avoid or mitigate any losses, damages or injury in respect of which it might
                                         be entitled to indemnification. The Indemnifying Party shall conduct the defense of the
                                         Third Party Claim in good faith using all the means and defenses reasonably available
                                         to it. The Indemnifying Party shall further keep the Indemnifiable Party informed of
                                         the developments of the underlying claim and its defense and shall promptly provide the
                                         Indemnifiable Party with all notices, communications and filings (including court papers)
                                         in relation thereto. No such claim or demand may be settled without the consent of the
                                         Indemnifiable Party, which consent shall not be unreasonably withheld or delayed.

 

    	 	15	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		10.3	Insurance.

 

During the term of this Agreement, each
Party shall subscribe and maintain adequate liability insurance to cover its obligations hereunder and shall provide evidence
thereof upon reasonable request of the other Party and, where feasible, advance notice, but in any event, written notice of any
pending termination or pending lapse of such insurance. The type and amount of insurance coverage required hereunder shall be
the same as that required under the Supply Agreement. Nothing in this Agreement may be construed to limit a party’s liability
hereunder to the amount of insurance carried by a Party.

 

		10.4	Limitation of Liability.

 

Except for SANOFI’s breach of Articles
7 or 11, Sections 10.1 or 10.2, or clauses (iv), (v) or (vi) of Section 4.1, the total sum recoverable against SANOFI by CPP in
respect of any and all claims, liabilities, obligations, judgments, penalties, losses, damages, costs and expenses (including,
without limitation, reasonable attorney’s fees) under this Agreement, other than under Section 10.1.1, shall not
exceed [*****].In no event shall either Party be liable to the other PaRty under or with
respect to this Agreement for any indirect, incidental, consequential, special or punitive damages of any kind, including any
loss of profits. The foregoing limits of liability shall not apply to any party’s indemnification obligations under
this Article 10.

 

		11	- CONFIDENTIALITY

 

11.1 Confidentiality Agreement.

 

The Parties hereby novate and incorporate
by reference into this Agreement that certain confidentiality agreement effective as of January 28, 2009 attached to the Supply
Agreement as Schedule 12.1, and hereby confirm its applicability to the terms of and transactions contemplated by this Agreement.
In addition, the Parties hereby extend the term of the obligations in the Confidentiality Agreement to a date which is ten years
after the later of the following: i) the Term of this Agreement; or ii) the term of any Intellectual Property Rights in the Improvements
or the Results, whichever is later.

 

    	 	16	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		11.2	No Publicity. 

 

Neither Party will issue or disseminate
any press release or statement, nor initiate any communication of information regarding the existence of the terms of this Agreement,
written or oral, to the communications media or a third party without the prior written consent of the other Party. The foregoing
shall not apply to required public releases necessary for compliance with Applicable Law in which case the Party making such disclosure
will consult with the other Party and take into consideration the comments of the other Party on the wording and timing of any
required public announcement. Both Parties agree that the names of the other Party, its officers, employees and agents will not
be used for purposes of any public commercial activity without their prior written consent.

 

		12	- FORCE MAJEURE

 

Neither party shall be liable for failure
or delays in performance of its obligations resulting from any event of force majeure, provided further that the party claiming
such excuse shall provide prompt written notice to the other setting forth the reason for and the estimated length of such delay,
which should not exceed one month and shall exert all reasonable commercial efforts to avoid or remedy such force majeure. If
the force majeure event is estimated to and/or lasts more than one month days, the Parties shall meet to agree on the appropriate
actions to take including but not limited to the possibility to terminate the Agreement in accordance with Section 8.1.

 

		13	- ASSIGNMENT - SUBCONTRACTING

 

		13.1	Assignment.

 

This Agreement shall be binding upon and
insure to the benefit of the Parties and their respective successors and permitted assigns. Nothing in this Agreement shall create
or be deemed to create any third party beneficiary rights in any person not Party to this Agreement. No assignment of this Agreement
or of any rights or obligations hereunder may be made by either Party without the prior written consent of the other Party and
any attempted assignment without such required consent shall be null and void, except that either Party may assign its rights
under this Agreement to an Affiliate or in connection with the purchase of all or substantially all of the assets pertaining the
DFMO Product and no such assignment will relieve the assigning Party of liability. It is understood between the Parties that such
approval shall not be unreasonably withheld.

 

		13.2	Subcontracting.

 

SANOFI may subcontract the performance
of certain of its obligations under a specific Statement of Work to qualified third parties, provided that (a) SANOFI notifies
CPP in writing in advance of the proposed subcontractor and identifies the specific Services to be performed by the subcontractor
and the subcontractor shall performs those Services in a manner consistent with and subject to the terms and conditions of this
Agreement, including without limitation the obligations under Articles 7 and 11, and (c) SANOFI shall remain liable for the performance
of the subcontractor. Additionally, Affiliates of SANOFI may perform Services under this Agreement or a Statement of Work for
SANOFI without the consent of CPP. For clarification, it is understood by the parties that the term “SANOFI” may be
understood to include subcontractors when describing tasks to be performed, where such subcontractors are authorized in accordance
with this section. If CPP advises SANOFI that CPP objects to the use of any particular subcontractor, SANOFI will duly consider
those objections in determining whether to retain the services of the subcontractor in performing the Services.

 

    	 	17	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		14	- MISCELLANEOUS PROVISIONS

 

14.1 Severability: The invalidity
or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision
of this Agreement, each of which shall remain in full force and effect and the invalidity and unenforceability of this Agreement
shall not affect the validity or enforceability in any jurisdiction in which such determination had not been made except to the
extent such invalidity or unenforceability causes this Agreement to no longer contain all of the material provisions reasonably
expected by the Parties to be contained. The Parties, however, agree to substitute any invalid or unenforceable provision by a
valid and enforceable provision which maintains, to the fullest extent possible, the respective interests of the Parties as established
by the present terms and conditions of the Agreement.

 

		14.2	Waiver: This Agreement may only
                                         be amended, supplemented or modified and any provision of this Agreement may only be
                                         waived, pursuant to a written instrument making specific reference to this Agreement
                                         and executed authorized representatives of the Parties.

 

		14.3	Notices: Unless otherwise specifically
                                         provided herein, all notices required or permitted by this Agreement shall be in writing
                                         and in English and shall be personally delivered, mailed by registered mail, sent by
                                         telefax with acknowledgement of receipt, or sent by DHL, or similar courier requiring
                                         signature on receipt, addressed to each Party’s respective address first listed
                                         above, as follows:

 

	CPP:	SANOFI:
	 	 
	Attention: Jeffrey E. Jacob, CEO	Attention: Sr. Director, CEPiA US
	Telephone: +1-520-908-7774	Telephone: +1 908 981-4986
	Telefax: +1-520-232-2191	Telefax: 1 908 9817981
	E-mail: jjacob@canprevent.com	E-mail Pierre.Bay@sanofi.com
	 	 
	with a copy to:	 
	cbrannen@canprevent.com	 

 

14.4 Entire Agreement: This Agreement,
the Exhibits hereto, and the provisions of the Supply Agreement to the extent they are referenced hereby or incorporated herein,
constitute the entire understanding and agreement between the Parties with respect to the matters herein and supersede any previous
agreements, understandings, or statement of intent in each case, written or oral, of every nature between the Parties with respect
to those matters. To the extent any provision of this Agreement is inconsistent with the provisions of a SOW, the provisions of
this Agreement shall prevail, unless a SOW specifically states that a particular term of the SOW shall control if conflicting
with this Agreement.

 

    	 	18	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

14.5.   Further Assurances:
Either party must take whatever additional action and execute whatever additional documents may be necessary or advisable
to fulfill its obligations under this Agreement.

 

14.6   Good Faith.
Each Party hereby warrants, represents, and attests to the other that it will exercise its good faith in performing under this
Agreement.

 

14.7   Counterparts.
This Agreement may be executed in two or more identical counterparts, each of which will be deemed to be an original, and
all of which, taken together, will constitute one and the same agreement. Delivery of an executed counterpart signature by electronic
mail in portable document format (.pdf) form, or by an other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same force and effect as physical delivery of the original paper document bearing the
original signature, and each Party may use electronic representations of this Agreement as evidence of the execution and delivery
of the Agreement by both Parties to the same extent that an original signature could be used.

 

14.8   Computation of
Time. In computing any period of time pursuant to this Agreement, the day or date of the act, notice, event, or default from
which the designated period of time begins to run will not be included. The last day of the period so computed will be included,
unless it is a Saturday, Sunday or federal holiday in the United States, in which event the period runs until the end of the next
day which is not a Saturday, Sunday or federal holiday

 

14.9   Independent Contractor.
This Agreement is not intended to create, nor should it be construed as creating, an agency, joint venture, partnership or
employer-employee relationship between SANOFI and CPP. Both Parties shall act solely as an independent contractor and shall have
no right to act for or to sign the name of the other Party in any way or to make quotations or to write letters under the name
of the other Party or to represent that the other Party is in any way responsible for any acts or omission of the Party.

 

14.10   Bilateral Warranties.
The representations and warranties of the Parties set forth in Section 9.1 of the Supply Agreement are hereby incorporated in
this Agreement, as if set forth in full, and reaffirmed by each Party.

 

    	 	19	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

		15	- GOVERNING LAW - DISPUTES

 

This Agreement shall be governed and construed
in accordance with the laws of New Jersey, without regard to the conflicts of law principles thereof.
Each Party may seek to enforce Articles 7 and 11 of this Agreement by equitable remedies, including without limitation
injunction and specific performance, in any court of competent jurisdiction. The remedies provided for hereunder are cumulative
and not exclusive to any remedy available at law or equity and are independent of all other remedies available at law or equity
and severally enforceable. The parties will make all reasonable efforts to resolve problems, complaints or disputes relating to
this Agreement, its construction or its breach (each a “Dispute”) by face-to-face, good faith
negotiations between senior executives. If those negotiations fail to resolve the Dispute within sixty days after being first
referred to their respective executive, then either party may bring judicial proceedings to resolve the matter in any state or
federal court of competent jurisdiction sitting in Wilmington, Delaware. The prevailing party in any judicial proceeding
regarding a dispute, controversy or claim is entitled to recover all of its costs and reasonable attorneys’ fees incurred
in each proceeding, including any and all appeals or petitions from any proceeding. The prevailing party will be determined by
the deciding tribunal based on which party succeeds in obtaining the relief, or in successfully obtaining or securing more of
the relief it sought than that sought by the opposing party(ies).

 

IN WITNESS WHEREOF THE PARTIES HAVE
CAUSED THIS AGREEMENT TO BE EXECUTED BY THEIR DULY AUTHORIZED REPRESENTATIVES.

 

Made in two (2) original copies.

 

	For SANOFI	 	For CPP
	 	 	 	 	 
	By: 	/s/ Paul Chew	 	By: 	/s/ Jeffrey Jacob
	on 1/9/12	 	on 10/19/12
	Name: Paul Chew	 	Name: Jeffrey Jacob
	Title:	 	Title:   CEO

 

    	 	20	 

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

EXHIBIT 1

[*****]

Scope for Phase [X] – Date [20__]

XYZ Product – Activity/Hours for
Development 

 

	 	Activity	Estimated

    Duration (Weeks)	Estimated
    Cost

    ($,€)
	Task
    1 
	1	[*****]	2
    – 3	 
	2	[*****]	13	 
	3	[*****]	1	 
	4	[*****]	5
    – 6	 
	5	[*****]	1
    – 2	 
	6	[*****]	1
    – 2	 
	Task
    2
	7	[*****]	8
    – 10	 
	8	[*****]	1	 
	9	[*****]	24	*
	10	[*****]	3
    – 4	 
	Task
    3
	11	[*****]	2
    – 3	 
	12	[*****]	2
    – 3	 
	13	[*****]	2
    – 3	 
	14	[*****]	2
    – 3	 
	15	[*****]	3
    – 4	 
	16	[*****]	1
    – 2	 
	17	[*****]	 	 
	Task
    4 
	18	[*****]	2	 
	19	[*****]	2
    – 3	 
	20	[*****]	 	***
	21	[*****]	26	 
	Total
    Estimated – (without optional costs)	TBD
	Total
    Estimated – (with all optional costs)	TBD

*Note 1

**Note 2

***Note 3

 

Operational Costs for Development (Phase
X): XYZ Product 

 

	Material	Estimated
    Costs ($US)
	Excipients	TBD
	API
    – XYZ	TBD
	API
    – 123	TBD
	Tooling	TBD
	Packaging	TBD
	Total	TBD

 

     

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

Combined Costs for Activity/Hours and
Operational Costs for Development (Phase X) XYZ Product 

 

	Expenditure	Estimated
    ($,€)
	Total
    Estimated for Activity/Hours – (without optional costs)	TBD
	Total
    Estimated for Activity/Hours – (with all optional costs)	TBD
	Total
    Estimated Operational Costs 	TBD
	Range
    of Total Estimated Activity/Hours & Operational Costs*	TBD

*Range is dependent on the optional
costs incurred

 

The above estimate for development hours
& costs are extracted from Sanofi and XYZ development metrics. This estimate is based on the s-a Industrial Development team
knowledge to date on the Eflornithine project and the associated estimated hours & costs for each individual task are success
driven. In the event that unforeseen events may arise during development, additional hours & costs may be required to complete
individual tasks or activities.

 

     

     

    

 

Portions herein identified by [*****] have been omitted
pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. A complete copy of
this document has been filed separately with the Securities and Exchange Commission

 

EXHIBIT 2 

CDA

Confidentiality Agreement effective
January 28, 2009

 

See Attached.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]